Satellos Bioscience Statistics
Want to see TSE:MSCL full AI Analyst Report?
Satellos Bioscience (MSCL) Stock Statistics & Valuation Metrics
Total Valuation
Satellos Bioscience has a market cap or net worth of CAD 203.04M. The enterprise value is CAD 180.84M.
- Market Cap
- CAD 203.04M
- Enterprise Value
- CAD 180.84M
Share Statistics
Satellos Bioscience has 21,216,438 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,216,438
- Owned by Insiders
- 6.67%
- Owned by Institutions
- 13.11%
Financial Efficiency
Satellos Bioscience’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -97.07%.
- Return on Equity (ROE)
- -0.91
- Return on Assets (ROA)
- -0.80
- Return on Invested Capital (ROIC)
- -97.07%
- Return on Capital Employed (ROCE)
- -0.97
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.41M
- Employee Count
- 18
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Satellos Bioscience is -3.17. Satellos Bioscience’s PEG ratio is 0.15.
- PE Ratio
- -3.17
- PS Ratio
- 0.00
- PB Ratio
- 2.86
- Price to FCF
- -4.29
- Price to Operating Cash Flow
- -4.28
- PEG Ratio
- 0.15
Income Statement
In the last 12 months, Satellos Bioscience had revenue of 0 and earned -25.31M in profits. Earnings per share was -1.73.
- Revenue
- 0
- Gross Profit
- -5,087
- Operating Income
- -26.92M
- Pretax Income
- -25.13M
- Net Income
- -25.31M
- EBITDA
- -26.92M
- Earnings Per Share (EPS)
- -1.73
Cash Flow
In the last 12 months, operating cash flow was -32.95M and capital expenditures -3,972, giving a free cash flow of -32.95M billion.
- Operating Cash Flow
- -32.95M
- Free Cash Flow
- -32.95M
- Free Cash Flow per Share
- -1.56
Dividends & Yields
Satellos Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.33%
- Earnings Yield
- -28.63%
Stock Price Statistics
- Beta
- 1.14
- 52-Week Price Change
- 14.73%
- 50-Day Moving Average
- 11.09
- 200-Day Moving Average
- 11.53
- Relative Strength Index (RSI)
- 44.58
- Average Volume (3m)
- 11.97K
Important Dates
Satellos Bioscience upcoming earnings date is Mar 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Satellos Bioscience as a current ratio of 7.77, with Debt / Equity ratio of 0.00%
- Current Ratio
- 7.77
- Quick Ratio
- 7.77
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.36
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Satellos Bioscience has paid 175.01K in taxes.
- Income Tax
- 175.01K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Satellos Bioscience EV to EBITDA ratio is -3.24, with an EV/FCF ratio of -4.10.
- EV to Sales
- 0.00
- EV to EBITDA
- -3.24
- EV to Free Cash Flow
- -4.10
- EV to Operating Cash Flow
- -4.10
Balance Sheet
Satellos Bioscience has CAD 52.67M in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of CAD 52.67M billion.
- Cash & Marketable Securities
- CAD 52.67M
- Total Debt
- CAD 0.00
- Net Cash
- CAD 52.67M
- Net Cash Per Share
- CAD 2.48
- Tangible Book Value Per Share
- CAD 2.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Satellos Bioscience is CAD 29.97, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CAD 29.97
- Price Target Upside
- 215.48% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -32.01%
Scores
- Smart Score
- 7
- AI Score
- 44
